Christoph Losem

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Medicine, Oncology, Pharmacology +6

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · Blood · 2009 · 157 citations

Medicine, Oncology, Pharmacotherapy +6

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Mathias Rummel, Ulrich Kaiser, Christina Balser et al. · The Lancet Oncology · 2015 · 153 citations

Medicine, Oncology, Pharmacotherapy +14

Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole

Axel Glasmacher, Christian Hahn, C Leutner et al. · Mycoses · 1999 · 147 citations

Medicine, Infectious Diseases, Pharmacology +17

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)

Rudolf Weide, H. Köppler, Jochen Heymanns et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2007 · 97 citations

Medicine, Oncology, Pharmacotherapy +14